You are here
MANDALMED, INC.
UEI: NPGNAQVJ3VZ7
# of Employees: 4
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: Yes
Award Charts
Award Listing
-
Novel Ex Vivo Gene Therapy for Spinal Cord Injury
Amount: $749,980.00DESCRIPTION (provided by applicant): There are approximately 10,000 traumatic spinal cord injuries in the United States each year. The average age of injury is 31 years. The majority (90%) of individu ...
SBIRPhase II2003Department of Health and Human Services National Institutes of Health -
NOVEL EX VIVO GENE THERAPY FOR SPINAL CORD INJURY
Amount: $155,695.00DESCRIPTION (provided by applicant): The goal of the Phase I research is to develop ex vivo gene therapy that will achieve long-term, localized delivery of human neurotrophin-3 (hNT-3) i ...
SBIRPhase I2002Department of Health and Human Services National Institutes of Health -
Novel Treatment for Breast Cancer: Truncated Galectin-3
Amount: $236,893.00DESCRIPTION (provided by applicant): Despite the available treatments breast cancer ranks second as the cause of death from cancer in women pri ...
SBIRPhase I2001Department of Health and Human Services National Institutes of Health -
N/A
Amount: $142,130.00N/A
SBIRPhase I2000Department of Health and Human Services National Institutes of Health -
GALECTIN 1 FOR MULTIPLE SCLEROSIS
Amount: $135,801.00N/A
SBIRPhase I1999Department of Health and Human Services -
THERAPY OF SPINAL CORD INJURY WITH NEUROTROPHIC FACTORS
Amount: $125,000.00N/A
STTRPhase I1999Department of Health and Human Services